Piper Sandler Maintains Overweight on AbbVie, Maintains $190 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Christopher Raymond maintains an Overweight rating on AbbVie (NYSE:ABBV) with a $190 price target.
July 02, 2024 | 5:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler analyst Christopher Raymond maintains an Overweight rating on AbbVie with a $190 price target, indicating confidence in the company's performance.
The reaffirmation of an Overweight rating and a $190 price target by Piper Sandler suggests strong confidence in AbbVie's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100